Okay, stop everything. I am not even joking when I say AbbVie is like that ex who just got a glow-up and now everyone’s obsessed. SKYRIZI® just got a double thumbs-up from Canada’s Drug Agency — first for Crohn’s, then for ulcerative colitis. Like, seriously? Two positive reimbursements back to back? That is the kind of attention no one sees coming but everyone drools over.
I mean, SKYRIZI® is basically flexing on inflammatory bowel diseases, telling Crohn’s and ulcerative colitis, “I got you.” And guess what? This isn’t some sketchy hype. They’ve got receipts — clinical trials like MOTIVATE, ADVANCE, FORTIFY, INSPIRE, COMMAND. Sounds like a secret club or those group chats that never end. But nope, just proof that this drug’s the real deal.
And then, AbbVie goes and signs a letter of intent with Canada’s big pharmaceutical squad, the pan-Canadian Pharmaceutical Alliance. Like, it’s that official “Let’s be besties” kind of move. It’s like when your messy ex finally texts “we should talk” and you’re lowkey curious but also kinda terrified. Except this time, the “talk” is about money and meds — which means AbbVie might be cashing in big time while helping people. Drama but make it wholesome?
Honestly, I can’t even with how AbbVie turned healthcare into a soap opera. One day, they’re the underdog, and the next? Total boss move with these drug approvals. It’s like they went from zero to hero in Canada overnight. And I’m here for the chaos because who knew watching health companies play chess was this juicy?
I’m just waiting for the next episode where AbbVie drops another bomb and the whole healthcare world loses it. Honestly, reading about these trials and deals feels like catching up on your favorite drama, but it’s about pills and policies. Who said stocks aren’t fun? They’re just complicated exes with better PR.
If you want to spill even more tea on big health moves, check out this roast on JNJ’s healthcare jump. Pure chaos, I swear.
Think you’re wired for chaos? Tap here.